Patents by Inventor Simon Hoerstrup

Simon Hoerstrup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bioengineered in vitro 3D model of human atherosclerotic plaque
    Patent number: 11946071
    Abstract: The invention provides a method for the generation of a layered cellular 3 D microtissue aggregate, comprising the steps of contacting myeloid cells with a protein kinase C agonist, yielding primed myeloid cells; incubating the primed myeloid cells in the presence of LDL in a confined volume, particularly in a hanging drop culture; yielding a 3 D culture of myeloid cells; and incubating the 3 D culture together with fibroblasts in a hanging drop in the presence of LDL, yielding the layered cellular aggregate.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: April 2, 2024
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Simon Hoerstrup, Benedikt Weber, Anna Mallone
  • BIOENGINEERED IN VITRO 3D MODEL OF HUMAN ATHEROSCLEROTIC PLAQUE
    Publication number: 20200325445
    Abstract: The invention provides a method for the generation of a layered cellular 3 D microtissue aggregate, comprising the steps of contacting myeloid cells with a protein kinase C agonist, yielding primed myeloid cells; incubating the primed myeloid cells in the presence of LDL in a confined volume, particularly in a hanging drop culture; yielding a 3 D culture of myeloid cells; and incubating the 3 D culture together with fibroblasts in a hanging drop in the presence of LDL, yielding the layered cellular aggregate.
    Type: Application
    Filed: August 23, 2018
    Publication date: October 15, 2020
    Inventors: Simon Hoerstrup, Benedikt Weber, Anna Mallone
  • AGONISTS OF THE NOGO-A S1PR PATHWAY FOR THE TREATMENT OF GLIOBLASTOMA
    Publication number: 20180015144
    Abstract: The invention relates to the use of an extracellular domain of Nogo selected from Nogo-A delta 20 and Nogo-66 for the treatment of glioblastoma, particularly by intravenous or intrathecal administration.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 18, 2018
    Applicant: UNIVERSITAT ZURICH
    Inventors: Thomas WALCHLI, Simon HOERSTRUP, Karl FREI, Martin SCHWAB, Andrin WACKER
  • NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES
    Publication number: 20180009907
    Abstract: Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 11, 2018
    Inventors: Chad Brokopp, Simon Hoerstrup
  • NOVEL ANTI-FIBROBLAST ACTIVATION PROTEIN (FAP) ANTIBODIES AND USES DERIVED THEREOF
    Publication number: 20170369592
    Abstract: Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
    Type: Application
    Filed: January 11, 2016
    Publication date: December 28, 2017
    Applicants: Mabimmune Diagostics AG, Neurimmune Holding AG, University of Zurich
    Inventors: Chad BROKOPP, Jan GRIMM, Benoit COMBALUZIER, Mareike GOERANSON, Christine LOHMANN, Simon HOERSTRUP, Roger NITSCH
  • NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES
    Publication number: 20150329646
    Abstract: Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.
    Type: Application
    Filed: May 11, 2015
    Publication date: November 19, 2015
    Inventors: Chad Brokopp, Simon Hoerstrup
  • Method for target and drug validation in inflammatory and/or cardiovascular diseases
    Patent number: 9034333
    Abstract: A novel method for validating the utility of a drug in the treatment of inflammatory and cardiovascular diseases is described.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: May 19, 2015
    Assignee: University of Zurich
    Inventors: Chad Brokopp, Simon Hoerstrup
  • METHOD FOR TARGET AND DRUG VALIDATION IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES
    Publication number: 20130164305
    Abstract: A novel method for validating the utility of a drug in the treatment of inflammatory and cardiovascular diseases is described.
    Type: Application
    Filed: August 29, 2011
    Publication date: June 27, 2013
    Applicant: University of Zurich
    Inventors: Chad Brokopp, Simon Hoerstrup
  • NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES
    Publication number: 20130156785
    Abstract: Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.
    Type: Application
    Filed: August 29, 2011
    Publication date: June 20, 2013
    Applicant: UNIVERSITY OF ZURICH
    Inventors: Chad Brokopp, Simon Hoerstrup